Ozempic is causing a sensation in the health industry: Originally a weight loss treatment, it is now clear the so-called GLP-1 drug can have positive effects on other health conditions such as diabetes. But for Australian investors, it means a string of household favorite stocks such as CSL and ResMed have been hit hard. Today we look at whether the 'Ozempic-sell off' may just be a rare opportunity to get into blue chips at a discount.
In this episode we cover whether the market impact of Ozempic is overstated, the high cost of your big dividends, the sorry tale of shares that go to zero, and will fewer workers mean less goes into super? 
Shareplicity author Danielle Ecuyer joins Wealth Editor James Kirby in today's episode